SUPPLEMENT

Q4 2023 — Other Financial Disclosures

Q4 2023PDF · 17 pages571 KB
Table 1: Sales by Segment 	1
Table 2: Sales by Geographic Area 	2
Table 3: Sales of Key Products/Franchises 	3 - 7
Table 3a: Supplemental Sales Reconciliation 	8
Table 4: Condensed Consolidated Statement of Earnings - QTD 	9
Table 5: Condensed Consolidated Statement of Earnings - YTD 	10
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 	11
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 	12
Table 8: Non-GAAP Adjusted Net Earnings 	13
Table 9: Non-GAAP IBT and R&D Expense by Segment - QTD 	14
Table 10: Non-GAAP IBT and R&D Expense by Segment - YTD 	15
Table 11: Non-GAAP P&L Reconciliation 	16
Fourth Quarter 2023
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
segment of business
Innovative Medicine (1,2)
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,604 	9.0 	9.0 	-
International 	5,643 	5,788 	(2.5) 	(3.1) 	0.6 	23,590 	23,959 	(1.5) 	(0.2) 	(1.3)
13,722 	13,163 	4.2 	4.0 	0.2 	54,759 	52,563 	4.2 	4.8 	(0.6)
Innovative Medicine excluding COVID-19 Vaccine (1,2)
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,484 	9.4 	9.4 	-
International 	5,599 	5,099 	9.8 	9.4 	0.4 	22,473 	21,900 	2.6 	4.3 	(1.7)
13,678 	12,474 	9.7 	9.5 	0.2 	53,642 	50,384 	6.5 	7.2 	(0.7)
MedTech
U.S. 	3,930 	3,445 	14.1 	14.1 	- 	15,275 	13,377 	14.2 	14.2 	-
International 	3,743 	3,331 	12.4 	12.8 	(0.4) 	15,125 	14,050 	7.7 	10.6 	(2.9)
7,673 	6,776 	13.3 	13.4 	(0.1) 	30,400 	27,427 	10.8 	12.4 	(1.6)
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,981 	10.6 	10.6 	-
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395 	19,939 	7.3 	7.2 	0.1 	85,159 	79,990 	6.5 	7.4 	(0.9)
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,861 	10.9 	10.9 	-
International 	9,342 	8,430 	10.8 	10.7 	0.1 	37,598 	35,950 	4.6 	6.7 	(2.1)
Worldwide excluding COVID-19 Vaccine (1)	
21,351	$ 	19,250 	10.9 % 	10.9 	0.0 	84,042	$ 	77,811 	8.0 % 	9.0 	(1.0)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
(2) Previously referred to as Pharmaceutical
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	12,009	$ 	10,820 	11.0 % 	11.0 	- 	46,444	$ 	41,981 	10.6 % 	10.6 	-
Europe 	4,962 	5,124 	(3.2) 	(5.8) 	2.6 	20,410 	20,664 	(1.2) 	(2.2) 	1.0
Western Hemisphere excluding U.S. 	1,166 	1,024 	14.0 	18.1 	(4.1) 	4,549 	4,108 	10.7 	15.8 	(5.1)
Asia-Pacific, Africa 	3,258 	2,971 	9.7 	12.1 	(2.4) 	13,756 	13,237 	3.9 	9.5 	(5.6)
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395	$ 	19,939 	7.3 % 	7.2 	0.1 	85,159	$ 	79,990 	6.5 % 	7.4 	(0.9)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
INNOVATIVE MEDICINE SEGMENT (2,3,4) 	2023 	2022 	Reported 	Operational (1) 	Currency 	2023 	2022 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	3,033	$ 	2,805 	8.1% 	8.1% 	- 	11,539	$ 	11,036 	4.6% 	4.6% 	-
Intl 	1,562 	1,312 	19.0% 	17.7% 	1.3% 	6,513 	5,899 	10.4% 	12.0% 	-1.6%
WW 	4,595 	4,118 	11.6% 	11.2% 	0.4% 	18,052 	16,935 	6.6% 	7.1% 	-0.5%
REMICADE
US 	294 	318 	-7.4% 	-7.4% 	- 	1,143 	1,417 	-19.3% 	-19.3% 	-
US Exports (5) 	35 	41 	-15.1% 	-15.1% 	- 	147 	204 	-28.0% 	-28.0% 	-
Intl 	100 	116 	-13.4% 	-12.4% 	-1.0% 	549 	722 	-23.9% 	-21.3% 	-2.6%
WW 	429 	475 	-9.6% 	-9.4% 	-0.2% 	1,839 	2,343 	-21.5% 	-20.7% 	-0.8%
SIMPONI / SIMPONI ARIA
US 	258 	280 	-7.8% 	-7.8% 	- 	1,124 	1,166 	-3.6% 	-3.6% 	-
Intl 	244 	220 	10.1% 	11.8% 	-1.7% 	1,073 	1,017 	5.4% 	9.3% 	-3.9%
WW 	502 	501 	0.1% 	0.8% 	-0.7% 	2,197 	2,184 	0.6% 	2.4% 	-1.8%
STELARA
US 	1,786 	1,621 	10.1% 	10.1% 	- 	6,966 	6,388 	9.0% 	9.0% 	-
Intl 	967 	764 	26.4% 	23.9% 	2.5% 	3,892 	3,335 	16.7% 	17.4% 	-0.7%
WW 	2,753 	2,386 	15.3% 	14.5% 	0.8% 	10,858 	9,723 	11.7% 	11.9% 	-0.2%
TREMFYA
US 	657 	541 	21.6% 	21.6% 	- 	2,147 	1,844 	16.5% 	16.5% 	-
Intl 	252 	211 	19.4% 	17.8% 	1.6% 	999 	824 	21.2% 	22.4% 	-1.2%
WW 	910 	752 	21.0% 	20.5% 	0.5% 	3,147 	2,668 	17.9% 	18.3% 	-0.4%
OTHER IMMUNOLOGY
US 	2 	3 	-22.8% 	-22.8% 	- 	11 	17 	-33.8% 	-33.8% 	-
Intl 	0 	0 	- 	- 	- 	0 	0 	- 	- 	-
WW 	2 	3 	-22.8% 	-22.8% 	- 	11 	17 	-33.8% 	-33.8% 	-
INFECTIOUS DISEASES
US 	353 	414 	-14.6% 	-14.6% 	- 	1,500 	1,680 	-10.7% 	-10.7% 	-
Intl 	498 	1,127 	-55.8% 	-58.2% 	2.4% 	2,918 	3,769 	-22.6% 	-23.9% 	1.3%
WW 	852 	1,540 	-44.7% 	-46.5% 	1.8% 	4,418 	5,449 	-18.9% 	-19.8% 	0.9%
COVID-19 VACCINE
US 	0 	0 	- 	- 	- 	0 	120 	* 	* 	-
Intl 	44 	689 	-93.7% 	-95.2% 	1.5% 	1,117 	2,059 	-45.8% 	-47.2% 	1.4%
WW 	44 	689 	-93.7% 	-95.2% 	1.5% 	1,117 	2,179 	-48.8% 	-50.1% 	1.3%
EDURANT / rilpivirine
US 	9 	9 	-12.4% 	-12.4% 	- 	35 	36 	-3.7% 	-3.7% 	-
Intl 	299 	281 	6.4% 	1.5% 	4.9% 	1,115 	972 	14.8% 	12.1% 	2.7%
WW 	307 	290 	5.8% 	1.0% 	4.8% 	1,150 	1,008 	14.1% 	11.5% 	2.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	341 	398 	-14.4% 	-14.4% 	- 	1,446 	1,494 	-3.2% 	-3.2% 	-
Intl 	98 	95 	3.1% 	-0.8% 	3.9% 	408 	449 	-9.2% 	-10.4% 	1.2%
WW 	439 	493 	-11.0% 	-11.8% 	0.8% 	1,854 	1,943 	-4.6% 	-4.9% 	0.3%
OTHER INFECTIOUS DISEASES
US 	4 	6 	-30.4% 	-30.4% 	- 	19 	30 	-34.5% 	-34.5% 	-
Intl 	58 	61 	-5.6% 	-4.9% 	-0.7% 	278 	289 	-3.8% 	-0.4% 	-3.4%
WW 	62 	67 	-7.8% 	-7.1% 	-0.7% 	297 	318 	-6.7% 	-3.6% 	-3.1%
% Change 	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported 	Operational (1) 	Currency 	2023 	2022 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	1,022 	912 	12.1% 	12.1% 	- 	4,065 	3,570 	13.9% 	13.9% 	-
Intl 	780 	825 	-5.5% 	-2.0% 	-3.5% 	3,076 	3,323 	-7.5% 	-3.7% 	-3.8%
WW 	1,801 	1,737 	3.7% 	5.4% 	-1.7% 	7,140 	6,893 	3.6% 	5.4% 	-1.8%
CONCERTA / Methylphenidate
US 	39 	37 	5.7% 	5.7% 	- 	230 	151 	52.5% 	52.5% 	-
Intl 	142 	131 	7.9% 	9.2% 	-1.3% 	554 	493 	12.2% 	16.4% 	-4.2%
WW 	180 	168 	7.4% 	8.5% 	-1.1% 	783 	644 	21.6% 	24.9% 	-3.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	733 	678 	8.0% 	8.0% 	- 	2,897 	2,714 	6.7% 	6.7% 	-
Intl 	278 	329 	-15.5% 	-15.7% 	0.2% 	1,218 	1,426 	-14.6% 	-12.8% 	-1.8%
WW 	1,011 	1,008 	0.3% 	0.3% 	0.0% 	4,115 	4,140 	-0.6% 	0.0% 	-0.6%
SPRAVATO
US 	180 	105 	72.3% 	72.3% 	- 	589 	328 	79.7% 	79.7% 	-
Intl 	26 	14 	87.1% 	83.4% 	3.7% 	100 	46 	* 	* 	*
WW 	206 	119 	74.1% 	73.6% 	0.5% 	689 	374 	84.1% 	84.0% 	0.1%
OTHER NEUROSCIENCE
US 	71 	91 	-23.0% 	-23.0% 	- 	349 	376 	-7.3% 	-7.3% 	-
Intl 	334 	351 	-5.0% 	3.2% 	-8.2% 	1,204 	1,358 	-11.3% 	-5.4% 	-5.9%
WW 	404 	442 	-8.7% 	-2.3% 	-6.4% 	1,553 	1,734 	-10.4% 	-5.9% 	-4.5%
ONCOLOGY
US 	2,285 	1,857 	23.0% 	23.0% 	- 	8,462 	6,930 	22.1% 	22.1% 	-
Intl 	2,334 	2,069 	12.8% 	12.0% 	0.8% 	9,199 	9,052 	1.6% 	2.9% 	-1.3%
WW 	4,618 	3,927 	17.6% 	17.2% 	0.4% 	17,661 	15,983 	10.5% 	11.2% 	-0.7%
CARVYKTI
US 	145 	54 	* 	* 	- 	469 	133 	* 	* 	-
Intl 	13 	- 	* 	* 	- 	30 	- 	* 	* 	-
WW 	159 	54 	* 	* 	500 	133 	* 	* 	*
DARZALEX
US 	1,395 	1,139 	22.5% 	22.5% 	- 	5,277 	4,210 	25.4% 	25.4% 	-
Intl 	1,155 	944 	22.3% 	21.8% 	0.5% 	4,467 	3,767 	18.6% 	20.2% 	-1.6%
WW 	2,550 	2,083 	22.4% 	22.2% 	0.2% 	9,744 	7,977 	22.2% 	22.9% 	-0.7%
ERLEADA
US 	287 	275 	4.4% 	4.4% 	- 	1,065 	968 	10.0% 	10.0% 	-
Intl 	361 	266 	35.6% 	34.0% 	1.6% 	1,322 	913 	44.8% 	46.0% 	-1.2%
WW 	647 	541 	19.8% 	19.0% 	0.8% 	2,387 	1,881 	26.9% 	27.5% 	-0.6%
IMBRUVICA
US 	255 	318 	-19.8% 	-19.8% 	- 	1,051 	1,390 	-24.4% 	-24.4% 	-
Intl 	533 	547 	-2.6% 	-3.8% 	1.2% 	2,214 	2,394 	-7.5% 	-6.7% 	-0.8%
WW 	788 	866 	-8.9% 	-9.7% 	0.8% 	3,264 	3,784 	-13.7% 	-13.2% 	-0.5%
ZYTIGA / abiraterone acetate
US 	9 	20 	-52.0% 	-52.0% 	- 	50 	74 	-32.1% 	-32.1% 	-
Intl 	191 	250 	-23.6% 	-23.2% 	-0.4% 	837 	1,696 	-50.7% 	-49.1% 	-1.6%
WW 	201 	270 	-25.6% 	-25.3% 	-0.3% 	887 	1,770 	-49.9% 	-48.4% 	-1.5%
OTHER ONCOLOGY
US 	192 	52 	* 	* 	- 	549 	156 	* 	* 	-
Intl 	82 	63 	32.2% 	28.4% 	3.8% 	330 	283 	16.9% 	17.0% 	-0.1%
WW 	274 	114 	* 	* 	* 	879 	438 	* 	* 	*
% Change 	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported 	Operational (1) 	Currency 	2023 	2022 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	733 	610 	20.2% 	20.2% 	- 	2,697 	2,346 	15.0% 	15.0% 	-
Intl 	282 	261 	8.6% 	10.9% 	-2.3% 	1,117 	1,071 	4.3% 	8.3% 	-4.0%
WW 	1,017 	870 	16.7% 	17.4% 	-0.7% 	3,815 	3,417 	11.6% 	12.9% 	-1.3%
OPSUMIT
US 	368 	305 	20.5% 	20.5% 	- 	1,292 	1,132 	14.1% 	14.1% 	-
Intl 	169 	156 	7.9% 	8.3% 	-0.4% 	681 	651 	4.6% 	7.2% 	-2.6%
WW 	536 	461 	16.2% 	16.3% 	-0.1% 	1,973 	1,783 	10.6% 	11.6% 	-1.0%
UPTRAVI
US 	348 	280 	24.3% 	24.3% 	- 	1,326 	1,104 	20.1% 	20.1% 	-
Intl 	70 	56 	26.4% 	31.4% 	-5.0% 	255 	218 	17.3% 	21.8% 	-4.5%
WW 	419 	336 	24.6% 	25.4% 	-0.8% 	1,582 	1,322 	19.7% 	20.4% 	-0.7%
OTHER PULMONARY HYPERTENSION
US 	18 	24 	-29.4% 	-29.4% 	- 	79 	110 	-28.6% 	-28.6% 	-
Intl 	45 	48 	-9.7% 	-3.9% 	-5.8% 	182 	202 	-10.3% 	-2.9% 	-7.4%
WW 	61 	73 	-16.2% 	-12.4% 	-3.8% 	260 	313 	-16.7% 	-12.0% 	-4.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	652 	776 	-15.9% 	-15.9% 	- 	2,906 	3,042 	-4.5% 	-4.5% 	-
Intl 	185 	194 	-4.7% 	-6.7% 	2.0% 	765 	845 	-9.4% 	-9.1% 	-0.3%
WW 	837 	971 	-13.7% 	-14.1% 	0.4% 	3,671 	3,887 	-5.5% 	-5.5% 	0.0%
XARELTO
US 	525 	667 	-21.2% 	-21.2% 	- 	2,365 	2,473 	-4.4% 	-4.4% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	525 	667 	-21.2% 	-21.2% 	- 	2,365 	2,473 	-4.4% 	-4.4% 	-
OTHER
US 	127 	110 	15.9% 	15.9% 	- 	541 	569 	-5.0% 	-5.0% 	-
Intl 	185 	194 	-4.7% 	-6.7% 	2.0% 	765 	845 	-9.4% 	-9.1% 	-0.3%
WW 	312 	304 	2.8% 	1.5% 	1.3% 	1,306 	1,414 	-7.6% 	-7.4% 	-0.2%
TOTAL INNOVATIVE MEDICINE
US 	8,079 	7,375 	9.5% 	9.5% 	- 	31,169 	28,604 	9.0% 	9.0% 	-
Intl 	5,643 	5,788 	-2.5% 	-3.1% 	0.6% 	23,590 	23,959 	-1.5% 	-0.2% 	-1.3%
WW 	13,722	$ 	13,163 	4.2% 	4.0% 	0.2% 	54,759	$ 	52,563 	4.2% 	4.8% 	-0.6%
See footnotes at end of schedule
% Change 	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDTECH SEGMENT (2,3) 	2023 	2022 	Reported 	Operational (1) 	Currency 	2023 	2022 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	971	$ 	603 	61.0% 	61.0% 	- 	3,633	$ 	2,169 	67.5% 	67.5% 	-
Intl 	698 	495 	40.8% 	41.7% 	-0.9% 	2,717 	2,131 	27.5% 	31.7% 	-4.2%
WW 	1,669 	1,098 	51.9% 	52.3% 	-0.4% 	6,350 	4,300 	47.7% 	49.8% 	-2.1%
ELECTROPHYSIOLOGY
US 	667 	547 	22.0% 	22.0% 	- 	2,458 	2,036 	20.7% 	20.7% 	-
Intl 	572 	447 	28.0% 	29.0% 	-1.0% 	2,230 	1,901 	17.3% 	21.5% 	-4.2%
WW 	1,239 	994 	24.7% 	25.2% 	-0.5% 	4,688 	3,937 	19.1% 	21.1% 	-2.0%
ABIOMED
US 	276 	31 	* 	* 	- 	1,066 	31 	* 	* 	-
Intl 	64 	- 	* 	* 	- 	240 	- 	* 	* 	-
WW 	340 	31 	* 	* 	- 	1,306 	31 	* 	* 	-
OTHER INTERVENTIONAL SOLUTIONS
US 	28 	25 	8.8% 	8.8% 	- 	109 	102 	6.7% 	6.7% 	-
Intl 	61 	48 	26.5% 	27.1% 	-0.6% 	247 	230 	7.3% 	11.4% 	-4.1%
WW 	89 	73 	20.4% 	20.7% 	-0.3% 	356 	332 	7.1% 	9.9% 	-2.8%
ORTHOPAEDICS
US 	1,425 	1,385 	2.9% 	2.9% 	- 	5,525 	5,321 	3.8% 	3.8% 	-
Intl 	843 	763 	10.5% 	8.8% 	1.7% 	3,417 	3,267 	4.6% 	5.8% 	-1.2%
WW 	2,268 	2,148 	5.6% 	5.0% 	0.6% 	8,942 	8,587 	4.1% 	4.6% 	-0.5%
HIPS
US 	266 	250 	6.3% 	6.3% 	- 	996 	943 	5.6% 	5.6% 	-
Intl 	132 	135 	-2.0% 	-3.9% 	1.9% 	564 	571 	-1.2% 	-0.1% 	-1.1%
WW 	398 	385 	3.4% 	2.7% 	0.7% 	1,560 	1,514 	3.0% 	3.5% 	-0.5%
KNEES
US 	242 	231 	4.5% 	4.5% 	- 	896 	851 	5.3% 	5.3% 	-
Intl 	144 	122 	18.1% 	15.6% 	2.5% 	559 	508 	10.2% 	11.1% 	-0.9%
WW 	387 	354 	9.2% 	8.4% 	0.8% 	1,456 	1,359 	7.1% 	7.5% 	-0.4%
TRAUMA
US 	487 	470 	3.6% 	3.6% 	- 	1,949 	1,882 	3.6% 	3.6% 	-
Intl 	255 	240 	5.9% 	4.1% 	1.8% 	1,030 	989 	4.1% 	4.8% 	-0.7%
WW 	741 	710 	4.4% 	3.8% 	0.6% 	2,979 	2,871 	3.8% 	4.0% 	-0.2%
SPINE, SPORTS & OTHER
US 	430 	434 	-0.7% 	-0.7% 	- 	1,684 	1,645 	2.4% 	2.4% 	-
Intl 	311 	265 	17.5% 	16.5% 	1.0% 	1,263 	1,198 	5.4% 	7.3% 	-1.9%
WW 	742 	699 	6.2% 	5.8% 	0.4% 	2,947 	2,843 	3.7% 	4.5% 	-0.8%
% Change 	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported 	Operational (1) 	Currency 	2023 	2022 	Reported 	Operational (1) 	Currency
SURGERY
US 	1,047 	1,000 	4.6% 	4.6% 	- 	4,031 	3,897 	3.4% 	3.4% 	-
Intl 	1,484 	1,383 	7.2% 	7.8% 	-0.6% 	6,006 	5,793 	3.7% 	7.0% 	-3.3%
WW 	2,530 	2,384 	6.1% 	6.4% 	-0.3% 	10,037 	9,690 	3.6% 	5.5% 	-1.9%
ADVANCED
US 	468 	456 	2.5% 	2.5% 	- 	1,833 	1,784 	2.8% 	2.8% 	-
Intl 	698 	653 	7.0% 	7.2% 	-0.2% 	2,837 	2,785 	1.9% 	5.1% 	-3.2%
WW 	1,167 	1,109 	5.1% 	5.2% 	-0.1% 	4,671 	4,569 	2.2% 	4.2% 	-2.0%
GENERAL
US 	579 	544 	6.4% 	6.4% 	- 	2,198 	2,113 	4.0% 	4.0% 	-
Intl 	785 	731 	7.4% 	8.3% 	-0.9% 	3,168 	3,008 	5.3% 	8.7% 	-3.4%
WW 	1,364 	1,275 	7.0% 	7.5% 	-0.5% 	5,366 	5,121 	4.8% 	6.8% 	-2.0%
VISION
US 	487 	456 	6.8% 	6.8% 	- 	2,086 	1,990 	4.8% 	4.8% 	-
Intl 	721 	689 	4.6% 	6.4% 	-1.8% 	2,986 	2,859 	4.5% 	7.9% 	-3.4%
WW 	1,208 	1,145 	5.5% 	6.6% 	-1.1% 	5,072 	4,849 	4.6% 	6.6% 	-2.0%
CONTACT LENSES / OTHER
US 	374 	343 	8.9% 	8.9% 	- 	1,626 	1,522 	6.8% 	6.8% 	-
Intl 	508 	489 	4.2% 	7.2% 	-3.0% 	2,076 	2,022 	2.7% 	7.0% 	-4.3%
WW 	882 	831 	6.1% 	7.9% 	-1.8% 	3,702 	3,543 	4.5% 	6.9% 	-2.4%
SURGICAL
US 	114 	113 	0.4% 	0.4% 	- 	460 	468 	-1.8% 	-1.8% 	-
Intl 	212 	200 	5.6% 	4.7% 	0.9% 	910 	837 	8.6% 	10.0% 	-1.4%
WW 	326 	314 	3.7% 	3.1% 	0.6% 	1,370 	1,306 	4.9% 	5.8% 	-0.9%
TOTAL MEDTECH
US 	3,930 	3,445 	14.1% 	14.1% 	- 	15,275 	13,377 	14.2% 	14.2% 	-
Intl 	3,743 	3,331 	12.4% 	12.8% 	-0.4% 	15,125 	14,050 	7.7% 	10.6% 	-2.9%
WW 	7,673	$ 	6,776 	13.3% 	13.4% 	-0.1% 	30,400	$ 	27,427 	10.8% 	12.4% 	-1.6%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Previously referred to as Pharmaceutical
(5) Reported as U.S. sales
% Change 	% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely

-- 8 of 17 --

2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Innovative Medicine
U.S. 	8,079	$ 	7,375 	9.5 % 	9.5 	- 	31,169	$ 	28,604 	9.0 % 	9.0 	-
International 	5,643 	5,788 	(2.5) 	(3.1) 	0.6 	23,590 	23,959 	(1.5) 	(0.2) 	(1.3)
Worldwide 	13,722 	13,163 	4.2 	4.0 	0.2 	54,759 	52,563 	4.2 	4.8 	(0.6)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,059 	(45.8) 	(47.2) 	1.4
Worldwide 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,179 	(48.8) 	(50.1) 	1.3
Innovative Medicine excluding COVID-19 Vaccine
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,484 	9.4 	9.4 	-
International 	5,599 	5,099 	9.8 	9.4 	0.4 	22,473 	21,900 	2.6 	4.3 	(1.7)
Worldwide 	13,678 	12,474 	9.7 	9.5 	0.2 	53,642 	50,384 	6.5 	7.2 	(0.7)
Worldwide
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,981 	10.6 	10.6 	-
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395 	19,939 	7.3 	7.2 	0.1 	85,159 	79,990 	6.5 	7.4 	(0.9)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,059 	(45.8) 	(47.2) 	1.4
Worldwide 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,179 	(48.8) 	(50.1) 	1.3
Worldwide
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,861 	10.9 	10.9 	-
International 	9,342 	8,430 	10.8 	10.7 	0.1 	37,598 	35,950 	4.6 	6.7 	(2.1)
Worldwide excluding COVID-19 Vaccine 	21,351	$ 	19,250 	10.9 % 	10.9 	- 	84,042	$ 	77,811 	8.0 % 	9.0 	(1.0)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FOURTH QUARTER 	TWELVE MONTHS
Percent Change 	Percent Change

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	21,395	$ 	100.0 	19,939	$ 	100.0 	7.3
Cost of products sold 	6,798 	31.8 	6,084 	30.5 	11.7
Gross Profit 	14,597 	68.2 	13,855 	69.5 	5.4
Selling, marketing and administrative expenses 	5,810 	27.1 	5,339 	26.8 	8.8
Research and development expense 	4,480 	20.9 	3,710 	18.6 	20.8
In-process research and development impairments 	58 	0.3 	173 	0.8
Interest (income) expense, net 	(212) 	(1.0) 	(77) 	(0.4)
Other (income) expense, net 	(421) 	(2.0) 	795 	4.0
Restructuring 	56 	0.3 	75 	0.4
Earnings before provision for taxes on income 	4,826 	22.6 	3,840 	19.3 	25.7
Provision for taxes on income 	694 	3.3 	613 	3.1 	13.2
Net earnings from Continuing Operations 	4,132	$ 	19.3 	3,227	$ 	16.2 	28.0
Net earnings/(loss) from Discontinued Operations, net of tax 	(83) 	293
Net earnings 	4,049	$ 	3,520	$
Net earnings per share (Diluted) from Continuing Operations 	1.70	$ 	1.22	$ 	39.3
Net earnings/(loss) per share (Basic/Diluted) from Discontinued Operations* 	(0.03)	$ 	0.11	$
Average shares outstanding (Diluted) 	2,430.7 	2,650.1
Effective tax rate from Continuing Operations 	14.4 % 	16.0 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	6,237	$ 	29.2 	6,482	$ 	32.5 	(3.8)
Net earnings from Continuing Operations 	5,562	$ 	26.0 	5,432	$ 	27.2 	2.4
Net earnings per share (Diluted) from Continuing Operations 	2.29	$ 	2.05	$ 	11.7
Effective tax rate from Continuing Operations 	10.8 % 	16.2 %
* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2023 	2022

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	85,159	$ 	100.0 	79,990	$ 	100.0 	6.5
Cost of products sold 	26,553 	31.2 	24,596 	30.7 	8.0
Gross Profit 	58,606 	68.8 	55,394 	69.3 	5.8
Selling, marketing and administrative expenses 	21,512 	25.2 	20,246 	25.3 	6.3
Research and development expense 	15,085 	17.7 	14,135 	17.7 	6.7
In-process research and development impairments 	313 	0.4 	783 	1.0
Interest (income) expense, net 	(489) 	(0.6) 	(214) 	(0.3)
Other (income) expense, net 	6,634 	7.8 	810 	1.0
Restructuring 	489 	0.6 	275 	0.4
Earnings before provision for taxes on income 	15,062 	17.7 	19,359 	24.2 	(22.2)
Provision for taxes on income 	1,736 	2.1 	2,989 	3.7 	(41.9)
Net earnings from Continuing Operations 	13,326	$ 	15.6 	16,370	$ 	20.5 	(18.6)
Net earnings from Discontinued Operations, net of tax 	21,827 	1,571
Net earnings 	35,153	$ 	17,941	$
Net earnings per share (Diluted) from Continuing Operations 	5.20	$ 	6.14	$ 	(15.3)
Net earnings per share (Diluted) from Discontinued Operations 	8.52	$ 	0.59	$
Average shares outstanding (Diluted) 	2,560.4 	2,663.9
Effective tax rate from Continuing Operations 	11.5 % 	15.4 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	29,811	$ 	35.0 	27,973	$ 	35.0 	6.6
Net earnings from Continuing Operations 	25,409	$ 	29.8 	23,796	$ 	29.7 	6.8
Net earnings per share (Diluted) from Continuing Operations 	9.92	$ 	8.93	$ 	11.1
Effective tax rate from Continuing Operations 	14.8 % 	14.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2023 	2022

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.2% 	13.3% 	7.3%
U.S. 	9.5% 	14.1% 	11.0%
International 	(2.5)% 	12.4% 	2.9%
WW Currency 	0.2 	(0.1) 	0.1
U.S. 	- 	- 	-
International 	0.6 	(0.4) 	0.2
WW Operational 	4.0% 	13.4% 	7.2%
U.S. 	9.5% 	14.1% 	11.0%
International 	(3.1)% 	12.8% 	2.7%
Abiomed 	(4.5) 	(1.6)
U.S. 	(7.2) 	(2.3)
International 	(1.9) 	(0.7)
All Other Acquisitions and Divestitures 	0.0 	0.2 	0.1
U.S. 	0.0 	0.3 	0.1
International 	0.1 	0.1 	0.1
WW Adjusted Operational 	4.0% 	9.1% 	5.7%
U.S. 	9.5% 	7.2% 	8.8%
International 	(3.0)% 	11.0% 	2.1%
Adjusted Operational Sales Growth
FOURTH QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.2% 	10.8% 	6.5%
U.S. 	9.0% 	14.2% 	10.6%
International 	(1.5)% 	7.7% 	1.9%
WW Currency 	(0.6) 	(1.6) 	(0.9)
U.S. 	- 	- 	-
International 	(1.3) 	(2.9) 	(1.9)
WW Operational 	4.8% 	12.4% 	7.4%
U.S. 	9.0% 	14.2% 	10.6%
International 	(0.2)% 	10.6% 	3.8%
Abiomed 	(4.7) 	(1.6)
U.S. 	(7.7) 	(2.5)
International 	(1.7) 	(0.6)
All Other Acquisitions and Divestitures 	0.1 	0.1 	0.1
U.S. 	0.0 	0.1 	0.1
International 	0.2 	0.1 	0.2
WW Adjusted Operational 	4.9% 	7.8% 	5.9%
U.S. 	9.0% 	6.6% 	8.2%
International 	0.0% 	9.0% 	3.4%
Adjusted Operational Sales Growth
TWELVE MONTHS 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2023 	2022 	2023 	2022
Net Earnings from Continuing Operations, after tax- as reported 	$4,132 	$3,227 	$13,326 	$16,370
Pre-tax Adjustments
Litigation related 	166 	262 	7,152 	866
Intangible Asset Amortization expense 	1,148 	977 	4,532 	3,944
COVID-19 Vaccine related costs 1 	10 	821 	663 	1,474
Restructuring related 2 	139 	119 	798 	372
Medical Device Regulation 3 	88 	88 	311 	296
Acquisition, integration and divestiture related 	237 	196 	339 	196
(Gains)/losses on securities 	(435) 	6 	641 	690
IPR&D impairments 	58 	173 	313 	783
Other 	- 	- 	- 	(7)
Tax Adjustments
Tax impact on special item adjustments 4 	75 	(394) 	(2,694) 	(1,294)
Tax legislation and other tax related 	(56) 	(43) 	28 	106
Adjusted Net Earnings from Continuing Operations, after tax 	$5,562 	$5,432 	$25,409 	$23,796
Average shares outstanding (Diluted) 	2,430.7 	2,650.1 	2,560.4 	2,663.9
Adjusted net earnings per share from Continuing Operations (Diluted) 	$2.29 	$2.05 	$9.92 	$8.93
Operational adjusted net earnings per share from Continuing Operations (Diluted) 	$2.28 	$9.89
Notes:
1
2
3
4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
Fourth Quarter 	Twelve Months Ended
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required
clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus
on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D
program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program,
hepatitis and HIV development. The restructuring expenses of $55 million in the quarter ($479 million Q4 YTD) include the termination of partnered and
non-partnered program costs and asset impairments.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting
certain markets, product lines and distribution network arrangements. The restructuring expenses of $84 million in the quarter ($319 million Q4 YTD)
primarily includes inventory and instrument reserves related to the market and product exits.
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a
replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were
required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change
and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech
operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed
during 2024.

-- 14 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations 	$ 	4,238 	3,223 	404 	806 	184 	(189) 	4,826 	3,840
% to Sales 	30.9% 	24.5% 	5.3% 	11.9% 	0.9% 	-0.9% 	22.6% 	19.3%
Intangible asset amortization expense 	747 	717 	401 	260 	- 	- 	1,148 	977
In-process research and development impairments 	- 	173 	58 	- 	- 	- 	58 	173
Litigation related 	17 	76 	149 	136 	- 	50 	166 	262
Loss/(gain) on securities 	(112) 	23 	(59) 	(17) 	(264) 	- 	(435) 	6
Restructuring related 	55 	31 	84 	88 	- 	- 	139 	119
Acquisition, integration and divestiture related 	175 	(104) 	62 	300 	- 	- 	237 	196
Medical Device Regulation 	- 	- 	88 	88 	- 	- 	88 	88
COVID-19 Vaccine related costs 	10 	821 	- 	- 	- 	- 	10 	821
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	5,130 	4,960 	1,187 	1,661 	(80) 	(139) 	6,237 	6,482
% to Sales 	37.4% 	37.7% 	15.5% 	24.5% 	-0.4% 	-0.7% 	29.2% 	32.5%
*Estimated as of 1/23/2024
As Reported Research and Development Expense 	$ 	3,357 	3,070 	1,123 	640 	4,480 	3,710
% to Sales 	24.5% 	23.3% 	14.6% 	9.4% 	20.9% 	18.6%
Q4 QTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 15 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations 	$ 	18,246 	15,647 	4,669 	4,447 	(7,853) 	(735) 	15,062 	19,359
% to Sales 	33.3% 	29.8% 	15.4% 	16.2% 	-9.2% 	-0.9% 	17.7% 	24.2%
Intangible asset amortization expense 	2,983 	2,911 	1,549 	1,033 	- 	- 	4,532 	3,944
In-process research and development impairments 	206 	783 	107 	- 	- 	- 	313 	783
Litigation related 	(108) 	104 	190 	612 	7,070 	150 	7,152 	866
Loss/(gain) on securities 	362 	696 	(102) 	(6) 	381 	- 	641 	690
Restructuring related 	479 	63 	319 	309 	- 	- 	798 	372
Acquisition, integration and divestiture related 	175 	(104) 	164 	300 	- 	- 	339 	196
Medical Device Regulation 	- 	- 	311 	296 	- 	- 	311 	296
COVID-19 Vaccine related costs 	663 	1,474 	- 	- 	- 	- 	663 	1,474
Other 	- 	- 	- 	- 	- 	(7) 	- 	(7)
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	23,006 	21,574 	7,207 	6,991 	(402) 	(592) 	29,811 	27,973
% to Sales 	42.0% 	41.0% 	23.7% 	25.5% 	-0.5% 	-0.7% 	35.0% 	35.0%
*Estimated as of 1/23/2024
As Reported Research and Development Expense 	$ 	11,963 	11,642 	3,122 	2,493 	15,085 	14,135
% to Sales 	21.8% 	22.1% 	10.3% 	9.1% 	17.7% 	17.7%
Q4 YTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 16 of 17 --

Fourth Quarter
Dec. 31, 2023
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Dec. 31, 2023
Non-GAAP
Cost of products sold 	6,798	$ 	(1,131) 	(83) 	(42) 	(12) 	- 	- 	5,530
Selling, marketing and admin expenses 	5,810 	(8) 	5,802
Research and development expense 	4,480 	(16) 	(38) 	(1) 	4,425
Other (Income) / Expense 	(421) 	(17) 	(166) 	- 	(221) 	435 	3 	- 	(387)
In-process research and development impairments 	58 	(58) 	-
Restructuring 	56 	(56) 	-
Provision for taxes on income 	694 	175 	(134) 	13 	16 	30 	(191) 	16 	- 	56 	- 	675
Net Earnings from Continuing Operations 	4,132 	973 	300 	45 	123 	207 	(244) 	72 	10 	(56) 	- 	5,562
Fourth Quarter
Jan. 1, 2023
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Jan. 1, 2023
Non-GAAP
Cost of products sold 	6,084	$ 	(977) 	(25) 	(33) 	(160) 	- 	- 	4,889
Selling, marketing and admin expenses 	5,339 	(9) 	5,330
Research and development expense 	3,710 	- 	(46) 	(114) 	3,550
Other (Income) / Expense 	795 	- 	(262) 	(19) 	(196) 	(6) 	(547) 	- 	(235)
In-process research and development impairments 	173 	(173) 	-
Restructuring 	75 	(75) 	-
Provision for taxes on income 	613 	148 	(36) 	40 	19 	5 	2 	17 	199 	43 	- 	1,050
Net Earnings from Continuing Operations 	3,227 	829 	298 	133 	100 	191 	4 	71 	622 	(43) 	- 	5,432
Twelve Months
Dec. 31, 2023
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Dec. 31, 2023
Non-GAAP
Cost of products sold 	26,553	$ 	(4,511) 	(309) 	(133) 	(189) 	21,411
Selling, marketing and admin expenses 	21,512 	(29) 	- 	21,483
Research and development expense 	15,085 	(32) 	(149) 	(99) 	14,805
Other (Income) / Expense 	6,634 	(21) 	(7,152) 	- 	(307) 	(641) 	(375) 	- 	(1,862)
In-process research and development impairments 	313 	(313) 	- 	- 	- 	- 	-
Restructuring 	489 	(489) 	-
Provision for taxes on income 	1,736 	707 	1,505 	70 	157 	52 	(9) 	57 	155 	(28) 	- 	4,402
Net Earnings from Continuing Operations 	13,326 	3,825 	5,647 	243 	641 	287 	650 	254 	508 	28 	- 	25,409
Twelve Months
Jan. 1, 2023
GAAP
Intangible asset
amortization 	Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Jan. 1, 2023
Non-GAAP
Cost of products sold 	24,596	$ 	(3,944) 	(62) 	(109) 	(456) 	20,025
Selling, marketing and admin expenses 	20,246 	(28) 	20,218
Research and development expense 	14,135 	- 	(159) 	(304) 	13,672
Other (Income) / Expense 	810 	- 	(866) 	(35) 	(196) 	(690) 	(714) 	7 	(1,684)
In-process research and development impairments 	783 	(783) 	- 	-
Restructuring 	275 	(275) 	-
Provision for taxes on income 	2,989 	590 	(125) 	178 	66 	5 	166 	56 	360 	(106) 	(2) 	4,177
Net Earnings from Continuing Operations 	16,370 	3,354 	991 	605 	306 	191 	524 	240 	1,114 	106 	(5) 	23,796
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Year to Date
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related

-- 17 of 17 --